Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00224289 · ClinicalTrials.gov registry record · Phase 4
Effect of Age on Latanoprost 0.005% in Patients With Glaucoma
A Phase 4 study, sponsored by Yale University.
- Completed
- Registry status
- Phase 4
- Development phase
- 17
- Enrollment target
NCT00224289 is a Phase 4 study that has completed, run by Yale University. The registered enrollment target is 17 participants.
The verdict
NCT00224289, a Phase 4 study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 17 participants
- Enrollment target
Study Summary
Latanoprost is a commonly used treatment for glaucoma. Because of its mechanism of action, it is plausible that the age of a patient using the medication may affect its efficacy and time of onset. We are going to study the effectiveness of Latanoprost in people of different ages, to see if it changes based on the age of the patient.
Interventions
- DRUG Latanoprost 0.005%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2005-03 |
| Est. Completion | 2009-04 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00224289
The ClinicalTrials.gov registry entry for NCT00224289 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Latanoprost 0.005% is the first listed.
NCT00224289 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00224289 about?
NCT00224289 is a clinical study titled "Effect of Age on Latanoprost 0.005% in Patients With Glaucoma". Latanoprost is a commonly used treatment for glaucoma. Because of its mechanism of action, it is plausible that the age of a patient using the medication may affect its efficacy and time of onset. We are going to study the effectiveness of Latanoprost in people of different ages, to see if it chang...
What is the current status of trial NCT00224289?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 17 participants. The study started on 2005-03. Estimated completion is 2009-04.
What interventions are being tested in trial NCT00224289?
The interventions under investigation include: Latanoprost 0.005% (DRUG).
Who is sponsoring clinical trial NCT00224289?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.